HOME › Press Releases › Immunoassay Market worth 25.45 Billion USD by 2021
Immunoassay Market worth 25.45 Billion USD by 2021
The report "Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software, Services), Technique (ELISA, Rapid Test), Application (Infectious Diseases, Endocrinology, Oncology), End User (Clinical Labs, Hospitals) - Global Forecast to 2021", report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the immunoassay market along with the estimates and forecasts of the revenue and market share analysis.
Browse 139 market data tables and 44 figures spread through 204 pages and in-depth TOC on “Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software, Services), Technique (ELISA, Rapid Test), Application (Infectious Diseases, Endocrinology, Oncology), End User (Clinical Labs, Hospitals) - Global Forecast to 2021”
Early buyers will receive 10% customization on reports.
The global immunoassay market is expected to reach USD 25.45 Billion by 2021 from USD 17.16 Billion in 2016, at a CAGR of 8.2% from 2016 to 2021. The major factors driving the growth of this market are rising incidences of chronic diseases, extensive use of immunoassays in oncology, technological advancements, and cost-effectiveness & rapid analysis of immunoassays.
This report segments the immunoassay market on the basis of product & service, technology, application, end user, and region. Based on product & service, the immunoassay market is segmented into reagents & kits, analyzers, and software & services. The reagents & kits segment is further segmented into ELISA reagents, rapid test reagents, western blot reagents, ELISPOT reagents, RIA reagents, and PCR reagents. The analyzers segment is further categorized into purchase mode and type. By purchase mode, the analyzers segment is segmented into reagent rental purchase and outright purchase and by type, these are divided into open-end systems and closed-ended systems.
In 2016, the reagents & kits segment is expected to dominate the global immunoassay market. Factors driving this segment include rising number of immunoassay tests due to the increase in aging population, rising prevalence of chronic and infectious diseases, and increased variety of reagents and analytical techniques.
Based on technology, the immunoassay market is segmented into ELISA, rapid tests, western blot tests, ELISPOT, RIA, and PCR. ELISA is further segmented into platform and generation. On the basis of platform, the ELISA market is divided into chemiluminescence immunoassays (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassays (CI). On the basis of generation, the ELISA market is further divided into first generation, second generation, third generation, and fourth generation and above. The ELISA segment is expected to account for the largest share of the market, owing to expanding use of immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring.
On the basis of application, the immunoassay market is segmented into infectious diseases, endocrinology, bone and mineral disorders, oncology, cardiology, hematology and blood screening, autoimmune diseases, toxicology, neonatal screening, and other applications. The infectious diseases segment is expected to account the largest market share in 2016.
On the basis of end user, the immunoassay market is segmented into hospitals, clinical laboratories, blood banks, research & academic laboratories, pharmaceutical companies, CROs, biotechnology companies, and other end users. The hospitals segment is expected to account for the largest share of the global immunoassay market in 2016. Major factors driving the growth of this market are the rising prevalence of chronic diseases and increasing healthcare infrastructure.
On the basis of region, the immunoassay market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as technological advancement in the immunoassay products and rising incidence of chronic diseases.
Key players in the immunoassay market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens AG (Germany), Abbott Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), and bioMérieux SA (France).
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India